HRP20171198T1 - Monoklonsko protutijelo protiv psećeg interleukina-31 - Google Patents
Monoklonsko protutijelo protiv psećeg interleukina-31 Download PDFInfo
- Publication number
- HRP20171198T1 HRP20171198T1 HRP20171198TT HRP20171198T HRP20171198T1 HR P20171198 T1 HRP20171198 T1 HR P20171198T1 HR P20171198T T HRP20171198T T HR P20171198TT HR P20171198 T HRP20171198 T HR P20171198T HR P20171198 T1 HRP20171198 T1 HR P20171198T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- cdr2
- cdr3
- amino acid
- antibody
- Prior art date
Links
- 102100021596 Interleukin-31 Human genes 0.000 title claims 9
- 101710181613 Interleukin-31 Proteins 0.000 title claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 238000006467 substitution reaction Methods 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 241000282465 Canis Species 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000001823 pruritic effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 206010027654 Allergic conditions Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (28)
1. Izolirano protutijelo koje se specifično veže na pseći IL-31, naznačeno time što navedeno protutijelo smanjuje, inhibira ili neutralizira pSTAT signaliziranje posredovano psećim IL-31 u ispitivanju baziranom na stanicama.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je navedeno protutijelo monoklonsko protutijelo.
3. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što je protutijelo kimerno.
4. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što je protutijelo kaninizirano.
5. Izolirano protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili njegov antigenski vežući dio, naznačeno time što sadrži najmanje jedno iz skupine koju čine:
područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog (VH) lanca, s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1), SYDMS (SEQ ID NO: 2; 19D07-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1);
CDR2 varijabilnog teškog lanca, s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2), TITSGGGYTYSADSVKG (SEQ ID NO: 5; 19D07-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2);
CDR3 varijabilnog teškog lanca, s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3), ARQNWVVGLAY (SEQ ID NO: 8; 19D07-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i
njegova varijanta s jednom ili više konzervativnih aminokiselinskih supstitucija u najmanje jednom od CDR1, CDR2 ili CDR3.
6. Izolirano protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili njegov antigenski vežući dio, naznačeno time što sadrži najmanje jedno iz skupine koju čine:
varijabilni laki (VL) lanac koji sadrži područje za određivanje komplementarnosti (CDR)1, s aminokiselinskim slijedom RASESVDNYGISFMH (SEQ ID NO: 10; 11E12-VL-CDR1), KSSQSLLNSGNOKNYLA (SEQ ID NO: 11; 19D07-VL-CDR1) ili KASQSVSFAGTGLMH (SEQ ID NO: 12; 34D03-VL-CDR1);
CDR2 varijabilnog lakog lanca, s aminokiselinskim slijedom RASNLES (SEQ ID NO: 13; 11E12-VL-CDR2), GASTRES (SEQ ID NO: 14; 19D07-VL-CDR2) ili RASNLEA (SEQ ID NO: 15; 34D03-VL-CDR2);
CDR3 varijabilnog lakog lanca, s aminokiselinskim slijedom QQSNKDPLT (SEQ ID NO: 16; 11E12-VL-CDR3), QNDYSYPYT (SEQ ID NO: 17; 19D07-VL-CDR3) ili QQSREYPWT (SEQ ID NO: 18; 34D03-VL-CDR3); i
njegova varijanta s jednom ili više konzervativnih aminokiselinskih supstitucija u najmanje jednom od CDR1, CDR2 ili CDR3.
7. Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što dodatno sadrži najmanje jedno iz skupine koju čine:
područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog lanca, s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1), SYDMS (SEQ ID NO: 2; 19D07-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1);
CDR2 varijabilnog teškog lanca, s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2), TITSGGGYTYSADSVKG (SEQ ID NO: 5; 19D07-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2);
CDR3 varijabilnog teškog lanca, s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3), ARQNWVVGLAY (SEQ ID NO: 8; 19D07-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i
njegova varijanta s jednom ili više konzervativnih aminokiselinskih supstitucija u najmanje jednom od CDR1, CDR2 ili CDR3.
8. Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time što sadrži najmanje jedno iz skupine koju čine:
a) varijabilni laki lanac, koji sadrži
DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVATYYCQQSNKDPLTFGAGTKLELK (SEQ ID NO: 19; MU-11E12-VL), DIVMTQTPLSLSVSPGEPASISCRASESVDNYGISFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQSNKDPLTFGAGTKLEIK (SEQ ID NO: 20; CAN-11E12-VL-cUn-FW2), DIVMTQTPLSLSVSPGEPASISCRASESVDNYGISFMHWFQQKPGQSPQLLIYRASNLESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQSNKDPLTFGAGTKLEIK (SEQ ID NO: 21; CAN-11E12-VL-cUn-13), DIVMSQSPSSLSVSAGDKVTMSCKSSQSLLNSGNQKNYLAWYQQKPWQPPKLLIYGASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPYTFGGGTKLEIK (SEQ ID NO: 22; MU-19D07-VL), EIVMTQSPASLSLSQEEKVTITCKSSQSLLNSGNQKNYLAWYQQKPGQAPKLLIYGASTRESGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQNDYSYPYTFGQGTKLEIK (SEQ ID NO: 23; CAN-19D07-VL-998-1), DILLTQSPASLAVSLGQRAIISCKASQSVSFAGTGLMHWYQQKPGQQPKLLIYRASNLEAGVPTRFSGSGSRTDFTLNIHPVEEEDAATYFCQQSREYPWTFGGGTKLEIK (SEQ ID NO: 24; MU-34D03-VL) ili EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK (SEQ ID NO: 25; CAN-34D03-VL-998-1);
b) varijabilni teški lanac, koji sadrži
QVQLQQSGAELVKPGASVKLSCKASGYTFKYYDINWVRQRPEQGLEWIGWIFPGDGG TKYNETFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARGGTSVIRDAMDYWGQGT SVTVSS (SEQ ID NO: 26; MU-11E12-VH), EVQLVQSGAEVKKPGASVKVSCKTSGYTFKYYDINWVRQAPGAGLDWMGWIFPGDG GTKYNETFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARGGTSVIRDAMDYWGQG TLVTVSS (SEQ ID NO: 27; CAN-11E12-VH-415-1), EVKLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQIPEKRLEWVATITSGGGYTYSADSVKGRFTISRDNARNTLYLQMSSLRSEDTAVYYCARQWVVGLAYWGQGTLVT VSA (SEQ ID NO: 28; MU-19D07-VH), EVQLVESGGDLVKPGGSLRLSCVASGFTFSSYDMSWVRQAPGKGLQWVATITSGGGYTYSADSVKGRFTISRDNARNTLYLQMNSLRSEDTAVYYCARQNWVVGLAYWGQGTLV TVSS (SEQ ID NO: 29; CAN-19D07-VH-400-1), EVQLVESGGDLVKPGGSLKLSCAASGFSFSNYGMSWVRQTPDKRLEWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCVRGYGYDTMDYWGQGTSV TVSS (SEQ ID NO: 30; MU-34D03-VH), ili EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTL VTVSS (SEQ ID NO: 31; CAN-34D03-VH-568-1); i
c) njihove varijante s jednom ili više konzervativnih aminokiselinskih supstitucija.
9. Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što protutijelo sadrži najmanje jedno iz skupine koju čine:
a) varijabilni laki lanac, koji sadrži
DILLTQSPASLAVSLGQRAIISCKASQSVSFAGTGLMHWYQQKPGQQPKLLIYRASNLEAGVPTRFSGSGSRTDFTLNIHPVEEEDAATYFCQQSREYPWTFGGGTKLEIK (SEQ ID NO: 24; MU-34D03-VL) ili EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK (SEQ ID NO: 25; CAN-34D03-VL-998-1);
b) varijabilni teški lanac, koji sadrži
EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGS YTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS (SEQ ID NO: 31; CAN-34D03-VH-568-1); i EVQLVESGGDLVKPGGSLKLSCAASGFSFSNYGMSWVRQTPDKRLEWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCVRGYGYDTMDYWGQGTSVTVSS (SEQ ID NO: 30; MU-34D03-VH), ili
c) njihove varijante s jednom ili više konzervativnih aminokiselinskih supstitucija.
10. Veterinarski pripravak, naznačen time što sadrži terapijski djelotvornu količinu protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
11. Stanica domaćin, naznačena time što proizvodi protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
12. Izolirana nukleinska kiselina koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što sadrži nukleinskokiselinski slijed koji kodira najmanje jedno iz skupine koju čine:
područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog (VH) lanca, s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1), SYDMS (SEQ ID NO: 2; 19D07-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1);
CDR2 varijabilnog teškog lanca, s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2), TITSGGGYTYSADSVKG (SEQ ID NO: 5; 19D07-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2);
CDR3 varijabilnog teškog lanca, s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3), ARQNWVVGLAY (SEQ ID NO: 8; 19D07-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i
njegova varijanta s jednom ili više konzervativnih aminokiselinskih supstitucija u najmanje jednom od CDR1, CDR2 ili CDR3, te koja dodatno sadrži nukleinskokiselinski slijed koji kodira najmanje jedno iz skupine koju čine:
varijabilni laki (VL) lanac koji sadrži područje za određivanje komplementarnosti (CDR)1, s aminokiselinskim slijedom RASESVDNYGISFMH (SEQ ID NO: 10; 11E12-VL-CDR1), KSSQSLLNSGNQKNYLA (SEQ ID NO: 11; 19D07-VL-CDR1) ili KASQSVSFAGTGLMH (SEQ ID NO: 12; 34D03-VL-CDR1);
CDR2 varijabilnog lakog lanca, s aminokiselinskim slijedom RASNLES (SEQ ID NO: 13; 11E12-VL-CDR2), GASTRES (SEQ ID NO: 14; 19D07-VL-CDR2) ili RASNLEA (SEQ ID NO: 15; 34D03-VL-CDR2);
CDR3 varijabilnog lakog lanca, s aminokiselinskim slijedom QQSNKDPLT (SEQ ID NO: 16; 11E12-VL-CDR3), QNDYSYPYT (SEQ ID NO: 17; 19D07-VL-CDR3) ili QQSREYPWT (SEQ ID NO: 18; 34D03-VL-CDR3); i
njegova varijanta s jednom ili više konzervativnih aminokiselinskih supstitucija u najmanje jednom od CDR1, CDR2 ili CDR3.
13. Vektor, naznačen time što sadrži nukleinsku kiselinu u skladu s patentnim zahtjevom 12.
14. Postupak proizvodnje protutijela, naznačen time što se sastoji u uzgoju stanice domaćina u skladu s patentnim zahtjevom 11 u uvjetima koji dovode do proizvodnje protutijela, te izoliranju protutijela iz stanice domaćina ili medija za uzgoj stanice domaćina.
15. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što je namijenjeno upotrebi u terapiji.
16. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što je namijenjeno upotrebi u liječenju stanja ili poremećaja koji se bira između pruritičnog stanja ili alergijskog stanja, gdje se liječenje sastoji u primjeni terapijski djelotvorne količine protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9.
17. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, namijenjeno upotrebi u skladu s patentnim zahtjevom 16, naznačeno time što se pruritično stanje bira iz skupine koju čine atopični dermatitis, egzem, psorijaza, skleroderma i pruritis.
18. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, namijenjeno upotrebi u skladu s patentnim zahtjevom 17, naznačeno time što je pruritično stanje atopični dermatitis.
19. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, namijenjeno upotrebi u skladu s patentnim zahtjevom 18, naznačeno time što je za pruritično stanje karakterističan svrbež.
20. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, namijenjeno upotrebi u skladu s patentnim zahtjevom 16, naznačeno time što se alergijsko stanje bira iz skupine koju čine alergijsko dermatitis, ljetni egzem, koprivnjača, sipljivost, upalna bolest dišnih puteva, ponavljajuća opstrukcijska dišnih puteva, preosjetljivost dišnih puteva, kronična opstrukcijska plućna bolest i upalni procesi do kojih dolazi zbog autoimunosti.
21. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što je namijenjeno upotrebi u liječenju psa kojem je to potrebno inhibiranjem aktivnosti IL-31.
22. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što je namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 16 do 20, gdje se terapijski djelotvorna količina protutijela primjenjuje u rasponu doza od 0,1-10 mg protutijela po kg tjelesne težine svaka dva tjedna ili mjesečno.
23. Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 16 do 22, naznačeno time što se protutijelo označeno ovdje kao CAN34D03-65 primjenjuje supkutano u dozi od 1,0 mg/kg, gdje CAN34D03-65 je predstavljeno s SEQ ID NO:31 (VH) u paru s SEQ ID NO: 25 (VL) na SEQ ID NO: 42 (HC-65) i SEQ ID NO: 44 (LC-κ).
24. Postupak detektiranja ili kvantificiranja IL-31 u uzorku, naznačen time što se postupak sastoji u:
(a) inkubiranju kliničkog ili biološkog uzorka koji sadrži IL-31 u prisutnosti protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 9; i
(b) detektiranju protutijela vezanog na IL-31 u uzorku.
25. Postupak u skladu s patentnim zahtjevom 24, naznačen time što je protutijelo obilježeno na detektibilan način.
26. Postupak u skladu s patentnim zahtjevom 25, naznačen time što protutijelo nije obilježeno i upotrebljava se u kombinaciji s drugim protutijelom, obilježenim na detektibilan način.
27. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što se specifično veže na područje između aminokiselinskih ostataka 95 i 125 psećeg IL-31 s aminokiselinskim slijedom SEQ ID NO: 32.
28. Protutijelo u skladu s patentnim zahtjevom 27, naznačeno time što se protutijelo specifično veže na područje između aminokiselinskih ostataka 102 i 122 psećeg IL-31 sa slijedom SEQ ID NO: 32.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161510268P | 2011-07-21 | 2011-07-21 | |
| EP12748547.2A EP2734549B1 (en) | 2011-07-21 | 2012-07-05 | Monoclonal antibody against dog interleukin-31 |
| PCT/IB2012/053450 WO2013011407A1 (en) | 2011-07-21 | 2012-07-05 | Interleukin-31 monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171198T1 true HRP20171198T1 (hr) | 2017-10-20 |
Family
ID=46704979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171198TT HRP20171198T1 (hr) | 2011-07-21 | 2017-08-03 | Monoklonsko protutijelo protiv psećeg interleukina-31 |
| HRP20201634TT HRP20201634T1 (hr) | 2011-07-21 | 2020-10-09 | Monoklonsko protutijelo protiv interleukina-31 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201634TT HRP20201634T1 (hr) | 2011-07-21 | 2020-10-09 | Monoklonsko protutijelo protiv interleukina-31 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US8790651B2 (hr) |
| EP (4) | EP3842456A1 (hr) |
| JP (1) | JP6022563B2 (hr) |
| KR (2) | KR101613024B1 (hr) |
| CN (2) | CN103890009B (hr) |
| AR (1) | AR087281A1 (hr) |
| AU (2) | AU2012285432C1 (hr) |
| BR (1) | BR112014001407A8 (hr) |
| CA (2) | CA2926379A1 (hr) |
| CY (2) | CY1119475T1 (hr) |
| DK (1) | DK2734549T3 (hr) |
| ES (2) | ES2827231T3 (hr) |
| HR (2) | HRP20171198T1 (hr) |
| HU (2) | HUE034282T2 (hr) |
| LT (2) | LT2734549T (hr) |
| ME (1) | ME02837B (hr) |
| MX (1) | MX349053B (hr) |
| PL (2) | PL3219729T3 (hr) |
| PT (2) | PT3219729T (hr) |
| RS (2) | RS60924B1 (hr) |
| SI (2) | SI2734549T1 (hr) |
| UY (1) | UY34206A (hr) |
| WO (1) | WO2013011407A1 (hr) |
| ZA (1) | ZA201400768B (hr) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050086628A (ko) * | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Ｃｄ25에 대한 인간 모노클로날 항체 |
| HUE060822T2 (hu) | 2006-12-29 | 2023-04-28 | Ossifi Mab Llc | Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával |
| EP2647388A1 (en) * | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Antibodies Against ERBB3 and Uses Thereof |
| CN101970488B (zh) | 2007-12-07 | 2014-06-18 | 津莫吉尼蒂克斯公司 | 对il-31特异的人源化抗体分子 |
| PT3195880T (pt) * | 2010-05-14 | 2020-02-21 | Amgen Inc | Formulações de anticorpos antiesclerostina de concentração elevada |
| EP4303236A3 (en) * | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2691092T3 (es) | 2012-08-21 | 2018-11-23 | Janssen Pharmaceutica Nv | Anticuerpos contra la risperidona y uso de los mismos |
| CN108640996A (zh) | 2012-08-21 | 2018-10-12 | 詹森药业有限公司 | 帕潘立酮的抗体及其用途 |
| ES2742287T3 (es) * | 2012-09-26 | 2020-02-13 | Univ Wuerzburg J Maximilians | Anticuerpos monoclonales contra el factor de diferenciación de crecimiento 15 (GDF-15) |
| CA2944989A1 (en) * | 2013-04-08 | 2014-10-16 | Cytodyn Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
| EP4067383A1 (en) * | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EP3466445A1 (en) * | 2013-11-06 | 2019-04-10 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
| US11072647B2 (en) * | 2013-12-19 | 2021-07-27 | Onsejo Nacional DE Investigation Cientiticay Tecnica | TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro |
| BR112016014293B1 (pt) | 2013-12-20 | 2023-11-21 | Intervet International B.V | Região de fragmento cristalizável canino, anticorpo caninizado, e,composição farmacêutica |
| MX2016008667A (es) * | 2013-12-30 | 2017-02-02 | Epimab Biotherapeutics Inc | Inmunoglobulina con fab en tandem y usos de esta. |
| EP3102939A4 (en) * | 2014-02-05 | 2018-02-28 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
| MX2016008794A (es) * | 2014-02-06 | 2016-10-13 | Arsanis Biosciences Gmbh | Secuencias de anticuerpos especificos para e. coli. |
| PT3653644T (pt) * | 2014-03-26 | 2023-12-19 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro |
| WO2015196142A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| US10849862B2 (en) * | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
| KR20170105558A (ko) | 2015-01-30 | 2017-09-19 | 각코우호우징 사이타마이카다이가쿠 | 항 alk2 항체 |
| CA2977257A1 (en) * | 2015-02-22 | 2016-08-25 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd137 |
| MY190209A (en) * | 2015-03-31 | 2022-04-05 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| CN114848823A (zh) * | 2015-04-14 | 2022-08-05 | 中外制药株式会社 | 包含il-31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物 |
| US11424061B2 (en) * | 2015-04-14 | 2022-08-23 | Hanchett Entry Systems, Inc. | Solenoid assembly actuation using resonant frequency current controller circuit |
| EP3284480A4 (en) | 2015-04-14 | 2018-12-05 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
| CN108289949B (zh) | 2015-05-29 | 2022-04-12 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
| CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
| JP6983371B2 (ja) * | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途 |
| EP3390449A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica N.V. | Antibodies to risperidone and use thereof |
| WO2017123745A1 (en) * | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| KR102469478B1 (ko) * | 2016-04-27 | 2022-11-23 | 벤치마크 애니멀 헬스 엘티디. | 개 아토피성 피부염의 치료 |
| CN113372446A (zh) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| US11434269B2 (en) * | 2016-06-15 | 2022-09-06 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
| PE20190418A1 (es) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| KR20240035625A (ko) * | 2016-09-21 | 2024-03-15 | 넥스트큐어 인코포레이티드 | Siglec-15를 위한 항체 및 이의 사용 방법 |
| SG10201913470SA (en) | 2016-11-08 | 2020-03-30 | Regeneron Pharma | Antigen-binding proteins that antagonize leptin receptor |
| WO2018089335A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
| CA3047221A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| US11680101B2 (en) * | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
| WO2018150265A1 (en) * | 2017-02-16 | 2018-08-23 | Xbiotech, Inc. | Treatment of hidradenitis suppurativa |
| US11319372B2 (en) | 2017-02-21 | 2022-05-03 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| AU2018246377A1 (en) * | 2017-03-31 | 2019-10-17 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| AU2018252546A1 (en) * | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
| TWI799417B (zh) * | 2017-05-26 | 2023-04-21 | 英商葛蘭素史克智慧財產發展有限公司 | 生物製藥組成物及相關方法 |
| US11525005B2 (en) * | 2017-06-01 | 2022-12-13 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| TWI726228B (zh) * | 2017-08-09 | 2021-05-01 | 國立臺灣大學 | Ｃｄ１４拮抗分子用於治療癌症 |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
| CN111511760B (zh) * | 2017-09-21 | 2023-10-03 | 感应检查疗法公司 | 对btn2具有特异性的抗体及其用途 |
| RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| WO2019086694A1 (en) | 2017-11-06 | 2019-05-09 | Geert Mudde | Il31 antigen and vaccine |
| WO2019104157A1 (en) * | 2017-11-21 | 2019-05-31 | The University Of Vermont And State Agricultural College | Highly specific zika neutralizing human antibodies |
| CN111448208B (zh) * | 2017-12-11 | 2024-02-27 | Ubi Ip控股公司 | 用于治疗和/或预防异位性皮肤炎的il-31肽免疫原及其剂型 |
| MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
| CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| AU2019219608A1 (en) * | 2018-02-09 | 2020-08-27 | Chugai Seiyaku Kabushiki Kaisha | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
| EP3765500A2 (en) * | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Interleukin-31 monoclonal antibodies for veterinary use |
| WO2019178601A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| CN112236523A (zh) * | 2018-03-16 | 2021-01-15 | 国立大学法人滋贺医科大学 | 降解和去除异常tdp-43的抗体片段 |
| CN112040980A (zh) * | 2018-04-06 | 2020-12-04 | 瑞泽恩制药公司 | 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体 |
| EP3798227A4 (en) * | 2018-05-09 | 2022-03-02 | Good T Cells, Inc. | EPITOPE OF A REGULATORY T-CELL SURFACE ANTIGEN AND ANTIBODY SPECIFIC BINDING TO IT |
| US20210214456A1 (en) * | 2018-06-13 | 2021-07-15 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| JP7155403B2 (ja) * | 2018-08-20 | 2022-10-18 | ファイザー・インク | 抗ｇｄｆ１５抗体、組成物および使用の方法 |
| SG11202106100VA (en) * | 2018-12-21 | 2021-07-29 | 23Andme Inc | Anti-il-36 antibodies and methods of use thereof |
| SG11202106478UA (en) | 2019-01-03 | 2021-07-29 | Invetx Inc | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| CA3132587A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| KR20220004979A (ko) * | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | 조작된 iga 항체 및 사용 방법 |
| MX2021013356A (es) * | 2019-05-03 | 2022-03-11 | Singapore Health Serv Pte Ltd | Tratamiento y prevencion de enfermedades metabolicas. |
| CN110283246A (zh) * | 2019-06-20 | 2019-09-27 | 长春西诺生物科技有限公司 | 一种抗猫细小病毒的猫源化基因工程抗体 |
| US11890353B2 (en) * | 2019-10-15 | 2024-02-06 | Northwestern University | Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| WO2021123091A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Canine interleukin-4 receptor alpha antibodies |
| MX2022007636A (es) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. |
| WO2021207242A2 (en) * | 2020-04-07 | 2021-10-14 | Fred Hutchinson Cancer Research Center | Anti-mesothelin antigen-binding molecules and uses thereof |
| EP4136106A1 (en) | 2020-04-17 | 2023-02-22 | Zoetis Services LLC | Canine antibody variants |
| BR112022020631A2 (pt) * | 2020-04-17 | 2022-11-29 | Zoetis Services Llc | Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula |
| WO2021217024A1 (en) * | 2020-04-24 | 2021-10-28 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
| WO2021223719A1 (zh) * | 2020-05-08 | 2021-11-11 | 亘喜生物科技（上海）有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| JP2023526225A (ja) | 2020-05-11 | 2023-06-21 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| MX2022014440A (es) * | 2020-05-22 | 2023-02-27 | Regeneron Pharma | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. |
| WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| EP4192502A1 (en) * | 2020-08-05 | 2023-06-14 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| FR3113458B1 (fr) | 2020-08-21 | 2022-10-14 | Purally | Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie |
| JP2023538098A (ja) * | 2020-08-21 | 2023-09-06 | ジェンザイム・コーポレーション | Ｆｇｆｒ３抗体および使用の方法 |
| AR123636A1 (es) | 2020-09-28 | 2022-12-28 | Zoetis Services Llc | Variantes de anticuerpos caninos |
| AU2021352395A1 (en) | 2020-09-29 | 2023-04-27 | Zoetis Services Llc | Feline antibody variants |
| MX2023004438A (es) * | 2020-10-15 | 2023-05-08 | Intervet Int Bv | Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino. |
| TW202221039A (zh) | 2020-10-19 | 2022-06-01 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
| US11739137B2 (en) * | 2020-10-30 | 2023-08-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies to SARS-CoV-2 nucleocapsid protein |
| US20230416356A1 (en) * | 2020-11-23 | 2023-12-28 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| JP2024503212A (ja) * | 2020-12-18 | 2024-01-25 | ゾエティス・サービシーズ・エルエルシー | ネコ科動物抗体の定常領域における変異 |
| WO2022165067A2 (en) | 2021-01-28 | 2022-08-04 | Zoetis Services Llc | Mutations in canine antibody constant regions |
| CN117222664A (zh) | 2021-01-29 | 2023-12-12 | 拜耳动物保健有限责任公司 | 用于破坏自身耐受的疫苗组合物 |
| EP4294462A1 (en) | 2021-02-22 | 2023-12-27 | Zoetis Services LLC | Horse il-31 induced pruritus model |
| JP2024512574A (ja) * | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法 |
| US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
| KR20240001704A (ko) * | 2021-04-23 | 2024-01-03 | 아스트라제네카 아베 | 항-i형 inf 수용체 항체 아니프롤루맙을 이용한 루푸스 신염의 치료 |
| AU2022331122A1 (en) | 2021-08-20 | 2024-02-15 | Intervet International B.V. | Homodimer fusion proteins for treating atopic dermatitis |
| WO2023111128A1 (en) | 2021-12-16 | 2023-06-22 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha ii |
| WO2023152486A1 (en) | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| WO2024057096A1 (en) | 2022-09-14 | 2024-03-21 | Ceva Sante Animale | Treatment of atopic dermatitis using self-replicating rna expressing il-31 |
| CN115505575B (zh) * | 2022-11-16 | 2023-03-24 | 中国科学院天津工业生物技术研究所 | 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
| US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
| US6471957B1 (en) * | 1998-05-29 | 2002-10-29 | Heska Corporation | Canine IL-4 immunoregulatory proteins and uses thereof |
| BR0009074A (pt) | 1999-03-18 | 2002-01-02 | Merck Patent Gmbh | Proteìna para bloquear adesão de plaqueta |
| EP1130098A3 (en) | 2000-02-29 | 2003-09-10 | Pfizer Products Inc. | Mammalian osteoregulins |
| US6989145B2 (en) | 2000-03-03 | 2006-01-24 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody and antibody fragment |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| US6818444B2 (en) * | 2000-08-04 | 2004-11-16 | Heska Corporation | Canine and feline proteins, nucleic acid molecules and uses thereof |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| CA2469833C (en) | 2001-12-21 | 2008-05-20 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| EP1476541B1 (en) | 2002-01-18 | 2008-07-16 | ZymoGenetics, Inc. | Cytokine (zcytor17 ligand) |
| US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| NZ543202A (en) * | 2003-05-31 | 2008-04-30 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| WO2006081573A2 (en) | 2005-01-28 | 2006-08-03 | Zymogenetics, Inc. | Homogeneous preparations of il-31 |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| MX2007009471A (es) | 2005-02-14 | 2008-02-15 | Zymogenetics Inc | Metodos de tratamiento de enfermedades que son mediadas por las celulas positivas al antigeno del linfocito cutaneo. |
| WO2006104978A2 (en) | 2005-03-25 | 2006-10-05 | Curagen Corporation | Antibodies against the tenascin major antigens |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
| WO2007133816A2 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| JP5230022B2 (ja) * | 2006-08-09 | 2013-07-10 | ベイラー リサーチ インスティテュート | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
| WO2008028192A2 (en) | 2006-09-01 | 2008-03-06 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| ES2658239T3 (es) | 2006-10-19 | 2018-03-08 | Csl Limited | Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13 |
| CN101970488B (zh) | 2007-12-07 | 2014-06-18 | 津莫吉尼蒂克斯公司 | 对il-31特异的人源化抗体分子 |
| PT2384326E (pt) * | 2008-08-20 | 2014-06-09 | Zoetis Llc | Compostos de pirrolo[2,3-d]pirimidina |
| WO2010027488A2 (en) | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| WO2011065935A1 (en) | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| NZ724971A (en) | 2010-02-24 | 2019-06-28 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2012288926A1 (en) | 2011-07-22 | 2014-01-16 | Glaxosmithkline Biologicals S.A. | PRAME purification |
| EP3765500A2 (en) * | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Interleukin-31 monoclonal antibodies for veterinary use |
-
2012
- 2012-06-28 US US13/536,081 patent/US8790651B2/en active Active
- 2012-07-05 BR BR112014001407A patent/BR112014001407A8/pt not_active Application Discontinuation
- 2012-07-05 EP EP20194926.0A patent/EP3842456A1/en active Pending
- 2012-07-05 LT LTEP12748547.2T patent/LT2734549T/lt unknown
- 2012-07-05 HU HUE12748547A patent/HUE034282T2/en unknown
- 2012-07-05 CN CN201280046131.2A patent/CN103890009B/zh active Active
- 2012-07-05 EP EP12748547.2A patent/EP2734549B1/en not_active Revoked
- 2012-07-05 RS RS20201227A patent/RS60924B1/sr unknown
- 2012-07-05 MX MX2014000803A patent/MX349053B/es active IP Right Grant
- 2012-07-05 SI SI201231038T patent/SI2734549T1/sl unknown
- 2012-07-05 KR KR1020147004364A patent/KR101613024B1/ko active IP Right Grant
- 2012-07-05 LT LTEP17168574.6T patent/LT3219729T/lt unknown
- 2012-07-05 DK DK12748547.2T patent/DK2734549T3/en active
- 2012-07-05 KR KR1020167004578A patent/KR101742928B1/ko active IP Right Review Request
- 2012-07-05 PT PT171685746T patent/PT3219729T/pt unknown
- 2012-07-05 WO PCT/IB2012/053450 patent/WO2013011407A1/en active Application Filing
- 2012-07-05 EP EP19196963.3A patent/EP3653645A1/en active Pending
- 2012-07-05 CA CA2926379A patent/CA2926379A1/en not_active Abandoned
- 2012-07-05 JP JP2014520753A patent/JP6022563B2/ja active Active
- 2012-07-05 SI SI201231847T patent/SI3219729T1/sl unknown
- 2012-07-05 ME MEP-2017-192A patent/ME02837B/me unknown
- 2012-07-05 PL PL17168574T patent/PL3219729T3/pl unknown
- 2012-07-05 RS RS20170846A patent/RS56268B1/sr unknown
- 2012-07-05 PL PL12748547T patent/PL2734549T3/pl unknown
- 2012-07-05 ES ES17168574T patent/ES2827231T3/es active Active
- 2012-07-05 AU AU2012285432A patent/AU2012285432C1/en active Active
- 2012-07-05 EP EP17168574.6A patent/EP3219729B1/en active Active
- 2012-07-05 CN CN201610117883.3A patent/CN105504059B/zh active Active
- 2012-07-05 CA CA2842475A patent/CA2842475C/en active Active
- 2012-07-05 PT PT127485472T patent/PT2734549T/pt unknown
- 2012-07-05 ES ES12748547.2T patent/ES2638340T3/es active Active
- 2012-07-05 HU HUE17168574A patent/HUE051068T2/hu unknown
- 2012-07-20 AR ARP120102662A patent/AR087281A1/es active IP Right Grant
- 2012-07-20 UY UY0001034206A patent/UY34206A/es active IP Right Grant
-
2014
- 2014-01-31 ZA ZA2014/00768A patent/ZA201400768B/en unknown
- 2014-06-12 US US14/302,730 patent/US20140286958A1/en not_active Abandoned
- 2014-07-08 US US14/325,541 patent/US9206253B2/en active Active
-
2016
- 2016-05-30 AU AU2016203590A patent/AU2016203590B2/en active Active
-
2017
- 2017-08-03 HR HRP20171198TT patent/HRP20171198T1/hr unknown
- 2017-08-24 CY CY20171100897T patent/CY1119475T1/el unknown
-
2018
- 2018-12-05 US US16/210,228 patent/US10421807B2/en active Active
-
2019
- 2019-08-13 US US16/539,455 patent/US20190389944A1/en active Pending
- 2019-08-14 US US16/540,483 patent/US10526405B2/en active Active
-
2020
- 2020-10-09 HR HRP20201634TT patent/HRP20201634T1/hr unknown
- 2020-11-13 CY CY20201101077T patent/CY1123791T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171198T1 (hr) | Monoklonsko protutijelo protiv psećeg interleukina-31 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2014511179A5 (hr) | ||
| HRP20170038T1 (hr) | Protutijela na il-6 i njihova uporaba | |
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| HRP20170324T1 (hr) | Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| JP2010507594A5 (hr) | ||
| SI2514436T1 (en) | IL-22 for use in the treatment of microbial diseases | |
| JP2009005695A5 (hr) | ||
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| JP2020511123A5 (hr) | ||
| CA2861793A1 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| JP2014523401A5 (hr) | ||
| JP2014534218A5 (hr) | ||
| JP2011509245A5 (hr) | ||
| JP2013121353A5 (hr) | ||
| JP2010523541A5 (hr) | ||
| JP2011522832A5 (hr) | ||
| US20170051053A1 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| DK2650310T3 (en) | The anti-ADAMTS-5 antibody, derivatives and uses thereof | |
| JP2016520595A5 (hr) | ||
| JP2011207882A5 (hr) |